AusperBio secured $120 million in a Series C to advance an oligonucleotide therapy for chronic hepatitis B through later-stage development. The funding is intended to push an HBV-directed program into Phase 3 testing and support commercialization plans, according to the company’s disclosed financing update. Separately, the field continues to emphasize RNA- and transcription-focused strategies aimed at challenging HBV biology—especially covalently closed circular DNA (cccDNA) regulation. The financing and the underlying science reinforce that oligonucleotide platforms remain a central battleground for functional cure ambitions.